Thymic Regeneration via NOD2 and miR29c Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The thymus, a crucial site for T cell development, is highly sensitive to damage from aging, infection, or cancer therapies, leading to prolonged T cell deficiency, and existing pathways for thymic regeneration are not fully understood.
Innovation Solution
Inhibition of NOD2, Rho GTPases, and/or microRNA 29c (miR29c) upregulates regenerative molecules like IL-22, IL-23, and BMP4 to promote thymic regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the thymus is damaged by aging, infection, or cancer therapies, then T cell development is impaired, but the thymus possesses remarkable regenerative capacity that is not fully understood
Solution Approach 1:
The patent segments the complex regeneration process by identifying distinct molecular pathways and key regulatory molecules (NOD2, Rho GTPases, miR29c) that control thymic regeneration. This segmentation allows for targeted intervention at specific molecular levels rather than attempting to understand or manipulate the entire complex system at once.
Solution Approach 2:
The patent introduces intermediary molecules and pathways as mediators between damage signals and regenerative outcomes. Specifically, it identifies NOD2, Rho GTPases, and miR29c as intermediary regulators that translate damage signals into coordinated regenerative responses involving IL-22, IL-23, and BMP4 production.
2Productivity
If regenerative molecules like IL-22, IL-23, and BMP4 are upregulated to promote thymic regeneration, then thymic recovery is enhanced, but this requires precise molecular control
Solution Approach 1:
The patent employs preliminary action by using inhibitors of NOD2, Rho GTPases, and miR29c to pre-condition the thymic environment before full regeneration occurs. These inhibitors are administered to block negative regulatory pathways in advance, priming the system for enhanced regenerative responses to subsequent therapies.
Solution Approach 2:
The patent changes key molecular parameters by modulating the activity levels of NOD2, Rho GTPases, and miR29c through pharmacological inhibition. This parameter change approach shifts the regulatory balance from a suppressed state to an activated regenerative state, thereby enhancing the production of IL-22, IL-23, and BMP4.
3Reliability
If NOD2, Rho GTPases, and miR29c are inhibited to upregulate regenerative molecules, then thymic regeneration is promoted, but the mechanism requires multiple molecular targets
Solution Approach 1:
The patent merges multiple molecular targeting strategies into a unified therapeutic approach. By combining inhibition of NOD2, Rho GTPases, and miR29c, the patent creates a synergistic effect where each targeted pathway contributes to the overall regenerative response, amplifying the therapeutic effect beyond what any single target could achieve alone.
Data Source
AI summary
Methods to promote thymic regeneration are described. The methods can inhibit nucleotide-binding oligomerization domain-containing protein 2 (NOD2), Rho GTPases, and/or microRNA 29c (miR29c). These inhibition methods can promote regenerative molecules, such as interleukin (IL)-22, IL-23, and/or bone morphogenetic protein 4 (BMP4). Promoting thymic regeneration can be beneficial in patients due to age, infection, or cancer therapies.